You are here

Takeda

Hospitals rationing immune disorder drug

Hospitals rationing immune disorder drug

Beckers Hospital Review

Human Immune Globulin Infusion

Flag link:

Takeda, Sosei form gastrointestinal disease R&D pact

Takeda, Sosei form gastrointestinal disease R&D pact

Fierce Biotech

gastrointestinal disease

Flag link:

Takeda staffers accuse drugmaker of favoring Shire employees during merger: report

Takeda staffers accuse drugmaker of favoring Shire employees during merger: report

Fierce Pharma

Flag link:

Drugmakers will profit from climate change, Morgan Stanley says

Drugmakers will profit from climate change, Morgan Stanley says

Beckers Hospital Review

Moderna Therapeutics

Flag link:

As Takeda absorbs Shire’s R&D ops, the focus is on replacing a centralized command model with a ‘light touch’ in a restructured global organization

As Takeda absorbs Shire’s R&D ops, the focus is on replacing a centralized command model with a ‘light touch’ in a restructured global organization

Endpoints

Flag link:

Takeda Eyes Additional Divestitures to Pare Down Shire Deal Debt

Takeda Eyes Additional Divestitures to Pare Down Shire Deal Debt

BioSpace

Flag link:

Takeda Receives 1st Stem Cell-Derived CAR-T From Kyoto University Collaboration

Takeda Receives 1st Stem Cell-Derived CAR-T From Kyoto University Collaboration

BioSpace

Kyoto University

Flag link:

Novartis wraps up acquisition of Takeda’s dry eye drug Xiidra

Novartis wraps up acquisition of Takeda’s dry eye drug Xiidra

Pharmaceutical Business Review

hdry eye disease

Flag link:

Takeda suffers another setback in its quest to expand myeloma drug’s reach — and blockbuster potential

Takeda suffers another setback in its quest to expand myeloma drug’s reach — and blockbuster potential

Endpoints

clinical trials

Flag link:

FDA approves GATTEX for children with short bowel syndrome

FDA approves GATTEX for children with short bowel syndrome

Pharmaceutical Business Review

short bowel syndrome

Flag link:

May 15 ASCO Quick Takes: After-hours pop for Iovance, MacroGenics; plus Takeda, Amgen, Forty Seven

May 15 ASCO Quick Takes: After-hours pop for Iovance, MacroGenics; plus Takeda, Amgen, Forty Seven

BioCentury

cervical cancer

non-small cell lung cancer

HER2-positive metastatic breast cancer

Flag link:

Takeda veterans, Frazier launch Phathom with $90M to develop GI drug vonoprazan

Takeda veterans, Frazier launch Phathom with $90M to develop GI drug vonoprazan

BioCentury

Frazier Healthcare

gastrointestinal

Flag link:

J&J's Ethicon Spends $400M for Takeda’s Fibrin Sealant Patch

J&J's Ethicon Spends $400M for Takeda’s Fibrin Sealant Patch

Medical Devices and Diagnostics Industry

Fibrin Sealant Patch

Flag link:

Takeda sells Shire’s Xiidra, transfers 400 staffers to Novartis in $3.4B deal

Takeda sells Shire’s Xiidra, transfers 400 staffers to Novartis in $3.4B deal

Fierce Pharma

dry eye disease

Flag link:

Novartis Considers Offer for Takeda Eye-Disease Assets

Novartis Considers Offer for Takeda Eye-Disease Assets

Bloomberg

Flag link:

Takeda’s Entyvio Ad Captures Struggle to Make Plans

Takeda’s Entyvio Ad Captures Struggle to Make Plans

Xtalks

inflammatory bowel disease

Flag link:

Takeda Unites San Diego Operations At New ‘Biotech-Style’ R&D Center

Takeda Unites San Diego Operations At New ‘Biotech-Style’ R&D Center

Xconomy

Flag link:

Big Pharma come together for better drug side effect detection

Big Pharma come together for better drug side effect detection

Pharma Times

Bristol-Myers Squibb

Gilead Sciences

International Working Group on Signal Detection and Management in Pharmacovigilance

pharmacovigilance

Flag link:

Takeda takes a cautious step into neurological gene therapy, inking preclinical deal with StrideBio

Takeda takes a cautious step into neurological gene therapy, inking preclinical deal with StrideBio

Endpoints

Flag link:

Takeda’s Entyvio Bests Humira in Head-to-Head UC Study

Takeda’s Entyvio Bests Humira in Head-to-Head UC Study

BioSpace

ulcerative colitis

Flag link:

Pages